Med. praxi. 2012;9(1):20-24

Overactive bladder in old age and treatment options in primary care

prof.MUDr.Eva Topinková, CSc.
Geriatrická klinika 1. LF UK a VFN Praha

Overactive bladder (OAB) is characterized by episodes of urgency, micturition frequency, nycturia and, in majority of patients by urge

incontinence. It occurs frequently in older people and the prevalence increases with advancing age. 11–16 % of adult population is affected

and up to 20–30 % of elderly persons above 70 years. The treatment of choice are antimuscarininc drugs which supress detrusor

contraction by mechanism of blocking M3 and M2 muscarinic receptors in the bladder. Although there are fewer studies in geriatric

population all consistently prove antimuscarinics superiority over placebo. In primary care trospium chlorid was released for non-regulated

primary care physician prescribing. The risk of potential central anticholinergic adverse events is very low because trospium chlorid

does not cross blood-brain barrier. It is suitable also for older OAB patients with complex pharmacological regimen as it has a low risk

of drug interactions. Scientific evidence is sufficient for behavioral therapy in OAB. However, its implementation may be limited due to

availability or ability of the older patient to cooperate. In case the OAB treatment started by primary care physician is not sufficiently

effective the patient should be referred to a specialist´s treatment.

Keywords: overactive bladder, urgency, urge incontinence, elderly, pharmacotherapy, antimuscarinic drugs, primary care

Published: February 13, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Topinková E. Overactive bladder in old age and treatment options in primary care. Med. praxi. 2012;9(1):20-24.
Download citation

References

  1. Zmrhal J, Topinková E, Zmrhalová B. Inkontinence moči u žen v seniu: Limity diagnostiky a léčby. Česká geriatrická revue 2006; 4(4): 189-200.
  2. Coll-Planas L, Denkinger MD, Nikolaus T. Relationship of urinary incontinence and late-life disability: implications for clinical work and research in geriatrics. Z Gerontol Geriatr. 2008; 41(4): 283-290. Go to original source... Go to PubMed...
  3. Topinková E, Jurásková D, Kučera Z, Müllerová N. Jakou péči poskytujeme pacientům s inkontinencí v rezidenčních zařízeních a v domácí péči? II. Diagnostické, léčebné a ošetřovatelské postupy u inkontinetních pacientů. Česká geriatrická revue 2009; 7(2): 82-89.
  4. DuBeau CE, Kuchel GA, Johnson T 2nd, Palmer MH, Wagg A. Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence. Neurourol Urodyn. 2010; 29(1): 165-178. Go to original source... Go to PubMed...
  5. Martan A, a kol. Inkontinence moči u žen a její medikamentozní léčba. Jessenius Maxdorf, Praha 2006: 83.
  6. Topinková E. Úskalí farmakologické léčby urgentní inkontinence a hyperaktivního měchýře ve stáří. Lékařské listy ZN, 2009; 18, příloha ze 2. 11. 2009: 21-24.
  7. Martan A. Přehled současné farmakoterapie inkontinence moči u žen. Farmakoterapie 2007; 3: 501-506.
  8. Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging 2005; 22: 1013-1028. Go to original source... Go to PubMed...
  9. Topinková E. Farmakologická léčba urgentní inkontinence a hyperaktivního měchýře u seniorů. Causa subita 2008; 11(1): 6-10.
  10. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur.J. Urology 2005; 48: 5-26. Go to original source... Go to PubMed...
  11. Chapple CR, Khullar V, Gabriel Z. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008; 54: 543-562. Go to original source... Go to PubMed...
  12. Biastre K, Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother. 2009; 43(2): 283-295. Go to original source... Go to PubMed...
  13. Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008; 71(3): 449-454. Go to original source... Go to PubMed...
  14. Krhut J, Slíva J. Trospium chlorid. Farmakoterapie 2006; 2(5): 509-513.
  15. Staskin DR. Trospium chloride: distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin. North Am. 2006; 33: 465-473. Go to original source... Go to PubMed...
  16. Staskin DR, Sand PK, Zinner NR, Dmochowski RR. Trospium Study Group: Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Urol. 2007; 178(3 Pt 1): 978-983; discussion 983-984.
  17. Wiedemann A, Neumann G, Neumister C, Kusche W, Schwantes V. Efficacy and Tolerability of Add-On Trospium Chloride in Patients with BPS and OAB. UroToday International Journal vol.2, April 2009, doi: 10.3834/uij.19445784.2009.04.02.
  18. Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005; 53(12): 2195-2201. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.